英語 での New drug development の使用例とその 日本語 への翻訳
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
-
Programming
Process of new drug development.
New drug development in the United States.
Mounting costs of new drug development.
No new drug development required.
Focusing efforts on speeding up the new drug development process.
We also support new drug development as a partner of pharmaceutical manufacturers.
Calls for new antibiotic therapies have been issued, but new drug development is becoming rarer.[15].
The new drug development that inhibits regulating factors of LPL activity that is critical for TG metabolism has been progressing on a fast track.
Medical costs are skyrocketing primarily because of the long time andgreat expense required for new drug development.
The process of new drug development has many stages.
Mapping the human genome has shed light on the causes of diseases,ushering in the age of new drug development using biotechnology.
Currently, in new drug development, animal experiments are conducted to confirm the efficacy and safety of drug- candidates, followed by clinical studies on humans subjects.
Linical focuses considerable effort on speeding up the new drug development process, to help accelerate time to market(TTM).
In the company, which does business in Hong Kong, the US, and Europe,I was engaged in translation and promotion of communications involved in new drug development, sales, and marketing.
Within the long, difficult new drug development process, clinical development is considered to hold the key to whether an NDA can be filed.
Our company was established inJune 2005 by nine members who was involved in new drug development in a major domestic pharmaceutical company.
Gemseki Inc. hopes to help facilitate biomedical collaboration between academia and companies,and to make contributions to humanity and society through revitalizing new drug development.
As a group of professionals in new drug development, we aim to be a true Clinical Development Partner to our clients.
According to the agreement, the Iranian government will establish a new drug development research center and clinical trial hospital in the Osong biomedical district over the next ten years.
Meanwhile, the practice of respiratory medicine has recently been transformed,such as molecular targeting agents and immunotherapy for lung cancer, and new drug development for interstitial pneumonia and rare lung diseases.
New drug development, beginning from scratch, is extremely expensive and time-consuming, taking an estimated $1 billion and more than 10 years to get each new compound to market,” says Jun O. Liu, Ph.
With the construction of the HP building,Taiho Pharmaceutical will speed up new drug development in an effort to promptly deliver innovative new drugs to patients and medical professionals.
Therefore, promoting new drug development outside the existing framework is a pressing issue, but some companies have withdrawn from the front lines of psychotropic drug development because of the low success rate of clinical trials.
Up to now, drug development in Taiwan has largely operated based on manufacturing contracts; however,successful new drug development has seen an increase in active support from Taiwanese government policy.
As specialists in new drug development, Linical aims to be a true“Clinical Development Partner to pharmaceutical companies,” always ready and able to provide wide-ranging support for the business activities of our clients.
Going forward, the company will establish and strengthen its network with venture businesses that have early seeds in the US, Europe, Israel, Japan, and elsewhere,in an effort to enhance its new drug development capabilities by actively accessing innovative technologies.
Purpose of the Business Partnership New drug development in recent years has expanded from the field of lifestyle-related conditions with a large market share, to the domain of unmet medical needs where there are no treatment modalities per se, or treatment satisfaction with existing pharmaceuticals is low.
The new drug development success rate is low, and enormous development costs are required over long time periods. For these reasons, pharmaceutical companies are accelerating a move towards purchasing the outcome of basic research and clinical trials from universities and venture companies, while promoting the selection of and concentration on development areas.